SCHEMBL1065165

SCHEMBL1065165

Brc1cccc(-c2cccnc2)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 4/20 0.68
CYP11B2 P19099 4/20 0.68
CYP2A6 P11509 3/20 0.62
ALDH1A1 P00352 3/20 0.62
CYP1A2 P05177 1/20 0.62
CYP3A4 P08684 1/20 0.62
MEN1 O00255 3/20 0.60
PSIP1 O75475 1/20 0.60
AXL P30530 1/20 0.60
MKNK1 Q9BUB5 1/20 0.60
MKNK2 Q9HBH9 1/20 0.60
CYP19A1 P11511 3/20 0.59
CYP17A1 P05093 1/20 0.53
KMO O15229 1/20 0.53
KDM4E B2RXH2 2/20 0.51
LMNA P02545 2/20 0.51
HPGD P15428 2/20 0.51
KMT2A Q03164 2/20 0.50
EPHX2 P34913 1/20 0.50
PRMT6 Q96LA8 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22418959 0.98 CYP11B1 (0.66) CYP11B1CYP11B2CYP2A6ALDH1A1CYP1A2
SCHEMBL2750529 0.96 CYP11B1 (0.64) CYP11B1CYP11B2CYP2A6ALDH1A1CYP1A2
SCHEMBL12129656 0.96 CYP11B1 (0.64) CYP11B1CYP11B2CYP2A6ALDH1A1CYP1A2
SCHEMBL5527671 0.96 CYP11B1 (0.64) CYP11B1CYP11B2CYP2A6ALDH1A1CYP1A2
SCHEMBL5527756 0.91 CYP11B1 (0.58) CYP11B1CYP11B2CYP2A6ALDH1A1CYP1A2
SCHEMBL17177981 0.90 CYP11B1 (0.61) CYP11B1CYP11B2CYP2A6ALDH1A1CYP1A2
SCHEMBL18682051 0.90 CYP11B1 (0.61) CYP11B1CYP11B2CYP2A6ALDH1A1CYP1A2
SCHEMBL12129644 0.88 CYP11B1 (0.59) CYP11B1CYP11B2CYP2A6ALDH1A1CYP1A2
SCHEMBL12576018 0.86 CYP11B1 (0.57) CYP11B1CYP11B2CYP2A6ALDH1A1CYP1A2
SCHEMBL3785592 0.86 CYP11B1 (0.53) CYP11B1CYP11B2CYP2A6ALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2445881-B1 PROCESS FOR MAKING ORGANIC COMPOUNDS AND THE ORGANIC COMPOUNDS MADE THEREFROM BOE TECHNOLOGY GROUP CO LTD (CN) 2017-11-15 EP claimed
CN-102574794-B Method for preparing organic compound and organic compound prepared thereby GENERAL ELECTRIC CO. (US) 2015-12-16 CN claimed
US-8426601-B2 Process for making organic compounds and the organic compounds made therefrom GENERAL ELECTRIC COMPANY (US) 2013-04-23 US claimed
US-20120178938-A1 PROCESS FOR MAKING ORGANIC COMPOUNDS AND THE ORGANIC COMPOUNDS MADE THEREFROM GENERAL ELECTRIC COMPANY (US) 2012-07-12 US claimed
CN-102574794-A Method for preparing organic compound and organic compound prepared thereby GEN ELECTRIC 2012-07-11 CN claimed
US-8178682-B2 Process for making organic compounds and the organic compounds made therefrom GENERAL ELECTRIC COMPANY (US) 2012-05-15 US claimed
US-20100331547-A1 PROCESS FOR MAKING ORGANIC COMPOUNDS AND THE ORGANIC COMPOUNDS MADE THEREFROM GENERAL ELECTRIC COMPANY (US) 2010-12-30 US claimed
EP-4618755-A1 INHIBITORS AND DEGRADERS OF PIP4K PROTEIN Larkspur Biosciences, Inc. (US) 2025-09-24 EP disclosed
US-20240400499-A1 NOVEL AMINO ACID DERIVATIVES PEPTIDREAM INC (JP) 2024-12-05 US disclosed
WO-2024107746-A1 INHIBITORS AND DEGRADERS OF PIP4K PROTEIN LARKSPUR BIOSCIENCES (US) 2024-05-23 WO disclosed
WO-2024107746-A1 INHIBITORS AND DEGRADERS OF PIP4K PROTEIN LARKSPUR BIOSCIENCES (US) 2024-05-23 WO disclosed
CN-112300134-B ASK1 inhibitor and derivative thereof, preparation method, pharmaceutical composition and application 中国药科大学 2023-04-21 CN disclosed
US-11133477-B2 Heterocyclic compound and organic light emitting element using same LT MATERIALS CO., LTD. (KR) 2021-09-28 US disclosed
US-20020188000-A1 Imidazo-pyridine derivatives as ligands for gaba receptors MERCK SHARP & DOHME LTD. (GB) 2002-12-12 US disclosed
EP-1235827-A2 IMIDAZO-PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LTD. (GB) 2002-09-04 EP disclosed
WO-2002038568-A1 IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LIMITED (GB) 2002-05-16 WO disclosed
WO-2001090108-A1 3-PHENYL-IMIDAZO-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LIMITED (GB) 2001-11-29 WO disclosed
WO-2001038326-A2 IMIDAZO-PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LIMITED (GB) 2001-05-31 WO disclosed
US-5128335-A Antibiotics MERCK & CO., INC. (US) 1992-07-07 US disclosed
EP-0481662-A1 2-Heteroarylphenyl-carbapenem antibacterial agents MERCK & CO. INC. (US) 1992-04-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020188000-A1 Imidazo-pyridine derivatives as ligands for gaba receptors GABRA3, GABRA2, GABRA1 CYP11B1 1303/4885CYP11B2 1107/4885CYP2A6 1007/4885
US-20100331547-A1 PROCESS FOR MAKING ORGANIC COMPOUNDS AND THE ORGANIC COMPOUNDS MADE THEREFROM CYP4F11, BCL6, CYP2F1 CYP11B1 19/4885CYP11B2 13/4885CYP2A6 41/4885
US-11133477-B2 Heterocyclic compound and organic light emitting element using same CRY1, CRY2, CYP1A1 CYP11B1 53/4885CYP11B2 64/4885CYP2A6 89/4885
US-20240400499-A1 NOVEL AMINO ACID DERIVATIVES BCAT1, BCAT2, PELP1 CYP11B1 4665/4885CYP11B2 4550/4885CYP2A6 4365/4885
US-20120178938-A1 PROCESS FOR MAKING ORGANIC COMPOUNDS AND THE ORGANIC COMPOUNDS MADE THEREFROM CYP2F1, CYP4F2, CYP1B1 CYP11B1 125/4885CYP11B2 102/4885CYP2A6 30/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.